Hematologic Oncology

The phase III COLUMBA study compared a subcutaneous formulation of daratumumab vs the intravenous form in patients with relapsed or refractory multiple myeloma.

A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML.

The PRECIS study looked at consolidation treatment with autologous stem cell transplantation vs whole-brain radiation therapy in younger patients with CNS lymphoma.

Although many immunotherapies for AML have been explored, none have ever been shown to reduced relapse rates.

Researchers have developed and validated a clinical scoring system that could help guide treatment decisions among patients with multiple myeloma.

Researchers examined the effect of early progression in a real-world setting of follicular lymphoma patients.

The DYNAMO study investigated the oral PI3K gamma inhibitor duvelisib in heavily pretreated indolent non-Hodgkin lymphoma patients.

In this study, single-agent ofatumumab did not show superiority to rituximab or obinutuzumab, raising the question of whether ofatumumab should have a role in the treatment of follicular lymphoma.

The final results of the LNH-PRO-05 study showed that a combination of antiproliferative and immunomodulatory agents with chemo had good outcomes in follicular lymphoma patients.

A study investigates the efficacy of a second AHCT or RVD consolidation post-AHCT intervention in transplantation-eligible myeloma patients with multiple myeloma.

Can lenalidomide maintenance significantly improve progression-free survival in patients with newly diagnosed myeloma?

Dr. Copelan discusses the use of chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma patients and how these therapies might improve upon the current standard of care.

Investigators evaluated whether AZD3463 can induce apoptosis in a dose-dependent manner in a subset of AML patients.

Researchers evaluated the primary mechanisms governing drug resistance and relapse in patients treated with crenolanib, an FLT3 inhibitor.

A phase I study examines the use of LCAR-B38M, a CAR T-cell therapy directed against BCMA, in patients with relapsed/refractory multiple myeloma.

The study also looked at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients.

A study investigates whether FL patients had fewer early disease progression events when assigned to treatment with obinutuzumab plus chemotherapy.

Is the continuation of maintenance rituximab beneficial post bendamustine plus rituximab treatment in FL Patients?

Dr. Daver discusses immunotherapy approaches for patients with acute myeloid leukemia (AML), and his recent study results on the combination of azacitidine and nivolumab.

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Guidelines for cancer screening in survivors of childhood HL may be refined based on the results of this extended follow-up study, say the researchers.

A new study published in Cancer compared ELN-2017 to ELN-2010 in terms of distinguishing prognosis in younger patients with newly diagosed AML.

Researchers reported on the impact of adding the Hedgehog pathway inhibitor glasdegib to low-dose cytarabine.

Researchers compared the ability of a novel prognostic score vs existing scores to identify patients with high-risk DLBCL.

In an interview with Cancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego.